Home > Archive > 2006 >

Volume 25, Number 4 (December)

Managing Glycemia in Type 2 Diabetes: Fresh Look (pages 3)

Daniel L. Lorber, M.D.

While the diabetes epidemic is growing, the number of tools currently available is also growing, making the physician’s approach more flexible but less clear. A new joint consensus report from experts in the U.S and Europe provides an excellent algorithm that emphasizes logical guiding principles.
Professional guidelines
Management strategies and toolsStrategies for glycemic control

Why Is There More Cardiovascular Disease in Diabetes? (pages 10-15)

Daniel L. Lorber, M.D.

There is no simple answer as to why there is more macrovascular disease in diabetes, but many factors have a negative impact on the vascular endothelium in diabetes. Dr. Lorber reviews what is known so far.
Complications and comorbiditiesCardiovascular disease

Dietary Protein and Its Influence on Diabetic Nephropathy (pages 16-22)

Madelyn L. Wheeler, M.S., R.D., C.D., F.A.D.A., C.D.E.

Is there a place for protein in the treatment of renal disease? What about the source of the protein? Will reducing intake reduce the progression of nephropathy? Ms. Wheeler reviews the evidence.
Diet therapy and nutrition
Complications and comorbiditiesNephropathy

Standards of Medical Care—2006 (Part 4) (pages 24-29)

American Diabetes Association

The 2006 Standards are significantly updated from earlier editions. This installment covers recommendations, screening, and treatment of renal disease—which has been significantly revised from earlier editionsŲ”nd retinopathy.
Complications and comorbiditiesNephropathy
Complications and comorbiditiesRetinopathy

Managing the Diabetic Patient in a Weight-Loss Program (pages 30-36)

L. Raymond Reynolds, M.D, F.A.C.P., F.A.C.E.

Losing weight can be very rewarding for people with Type 2 diabetes, resulting in improved glycemic control. But caloric restriction can increase the risk of hypoglycemia and electrolyte disturbances unless the patient is carefully supervised. Here is what you need to know to ensure safety for your patient who is in a weight-loss program.
Diet therapy and nutrition
Management strategies and toolsWeight loss

Metformin-Suppressible Primary Hyperaldosteronism (pages 37-39)

Alan Sacerdote, M.D., F.A.C.P., Mark L'Epplatanier, R.P.A., Alireza Toossi, M.D., Gul Bahtiyar, M.D., and Emad Girgis, M.D.

The authors report details of two cases of primary hyperaldosteronism that were metformin-suppressible and therefore likely to be due, at least in part, to insulin resistance.
Complications and comorbiditiesHyperaldosteronism
Drug treatmentMetformin